119 related articles for article (PubMed ID: 38258677)
1. Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial.
Due Bruun K; Christensen R; Amris K; Vaegter HB; Blichfeldt-Eckhardt MR; Bye-Møller L; Holsgaard-Larsen A; Toft P
Lancet Rheumatol; 2024 Jan; 6(1):e31-e39. PubMed ID: 38258677
[TBL] [Abstract][Full Text] [Related]
2. Colchicine twice a day for hand osteoarthritis (COLOR): a double-blind, randomised, placebo-controlled trial.
Døssing A; Henriksen M; Ellegaard K; Nielsen SM; Stamp LK; Müller FC; Kloppenburg M; Haugen IK; McCarthy GM; Conaghan PG; Ulff-Møller Dahl L; Terslev L; Altman RD; Becce F; Ginnerup-Nielsen E; Jensen L; Boesen M; Christensen R; Dal U; Bliddal H
Lancet Rheumatol; 2023 May; 5(5):e254-e262. PubMed ID: 38251589
[TBL] [Abstract][Full Text] [Related]
3. Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial.
Bruun KD; Amris K; Vaegter HB; Blichfeldt-Eckhardt MR; Holsgaard-Larsen A; Christensen R; Toft P
Trials; 2021 Nov; 22(1):804. PubMed ID: 34781989
[TBL] [Abstract][Full Text] [Related]
4. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.
Younger J; Noor N; McCue R; Mackey S
Arthritis Rheum; 2013 Feb; 65(2):529-38. PubMed ID: 23359310
[TBL] [Abstract][Full Text] [Related]
5. Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial.
Collins SE; Duncan MH; Saxon AJ; Taylor EM; Mayberry N; Merrill JO; Hoffmann GE; Clifasefi SL; Ries RK
Lancet Psychiatry; 2021 Apr; 8(4):287-300. PubMed ID: 33713622
[TBL] [Abstract][Full Text] [Related]
6. Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.
Schmidt-Kraepelin C; Feyerabend S; Engelke C; Riesbeck M; Meisenzahl-Lechner E; Verde PE; Correll CU; Kluge M; Makiol C; Neff A; Lange C; Englisch S; Zink M; Langguth B; Poeppl TB; Reske D; Gouzoulis-Mayfrank E; Gründer G; Hasan A; Brockhaus-Dumke A; Jäger M; Baumgärtner J; Leucht S; Cordes J;
Lancet Psychiatry; 2022 Apr; 9(4):291-306. PubMed ID: 35276079
[TBL] [Abstract][Full Text] [Related]
7. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
Giudice LC; As-Sanie S; Arjona Ferreira JC; Becker CM; Abrao MS; Lessey BA; Brown E; Dynowski K; Wilk K; Li Y; Mathur V; Warsi QA; Wagman RB; Johnson NP
Lancet; 2022 Jun; 399(10343):2267-2279. PubMed ID: 35717987
[TBL] [Abstract][Full Text] [Related]
8. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
[TBL] [Abstract][Full Text] [Related]
9. Gabapentin for chronic pelvic pain in women (GaPP2): a multicentre, randomised, double-blind, placebo-controlled trial.
Horne AW; Vincent K; Hewitt CA; Middleton LJ; Koscielniak M; Szubert W; Doust AM; Daniels JP;
Lancet; 2020 Sep; 396(10255):909-917. PubMed ID: 32979978
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Reich DS; Arnold DL; Vermersch P; Bar-Or A; Fox RJ; Matta A; Turner T; Wallström E; Zhang X; Mareš M; Khabirov FA; Traboulsee A;
Lancet Neurol; 2021 Sep; 20(9):729-738. PubMed ID: 34418400
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of erenumab in patients with trigeminal neuralgia in Denmark: a double-blind, randomised, placebo-controlled, proof-of-concept study.
Schott Andersen AS; Maarbjerg S; Noory N; Heinskou TB; Forman JL; Cruccu G; Ashina M; Bendtsen L
Lancet Neurol; 2022 Nov; 21(11):994-1003. PubMed ID: 36113495
[TBL] [Abstract][Full Text] [Related]
12. Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial.
Krupitsky E; Blokhina E; Zvartau E; Verbitskaya E; Lioznov D; Yaroslavtseva T; Palatkin V; Vetrova M; Bushara N; Burakov A; Masalov D; Mamontova O; Langleben D; Poole S; Gross R; Woody G
Lancet HIV; 2019 Apr; 6(4):e221-e229. PubMed ID: 30880163
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Cree BAC; Cutter G; Wolinsky JS; Freedman MS; Comi G; Giovannoni G; Hartung HP; Arnold D; Kuhle J; Block V; Munschauer FE; Sedel F; Lublin FD;
Lancet Neurol; 2020 Dec; 19(12):988-997. PubMed ID: 33222767
[TBL] [Abstract][Full Text] [Related]
14. Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial.
Schett G; Bainbridge C; Berkowitz M; Davy K; Fernandes S; Griep E; Harrison S; Gupta A; Lloyd-Hughes J; Roberts A; Layton M; Nowak NA; Patel J; Rech J; Smith JE; Watts S; Tak PP
Lancet Rheumatol; 2020 Oct; 2(10):e623-e632. PubMed ID: 38273625
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial.
Howard R; Cort E; Bradley R; Harper E; Kelly L; Bentham P; Ritchie C; Reeves S; Fawzi W; Livingston G; Sommerlad A; Oomman S; Nazir E; Nilforooshan R; Barber R; Fox C; Macharouthu AV; Ramachandra P; Pattan V; Sykes J; Curran V; Katona C; Dening T; Knapp M; Gray R;
Lancet Psychiatry; 2018 Jul; 5(7):553-563. PubMed ID: 29880238
[TBL] [Abstract][Full Text] [Related]
16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
17. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
Laterre PF; Colin G; Dequin PF; Dugernier T; Boulain T; Azeredo da Silveira S; Lajaunias F; Perez A; François B
Lancet Infect Dis; 2019 Jun; 19(6):620-630. PubMed ID: 31056427
[TBL] [Abstract][Full Text] [Related]
18. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
Schoser B; Roberts M; Byrne BJ; Sitaraman S; Jiang H; Laforêt P; Toscano A; Castelli J; Díaz-Manera J; Goldman M; van der Ploeg AT; Bratkovic D; Kuchipudi S; Mozaffar T; Kishnani PS;
Lancet Neurol; 2021 Dec; 20(12):1027-1037. PubMed ID: 34800400
[TBL] [Abstract][Full Text] [Related]
20. Results of a 6-week treatment with 10 mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial.
Kroon FPB; Kortekaas MC; Boonen A; Böhringer S; Reijnierse M; Rosendaal FR; Riyazi N; Starmans M; Turkstra F; van Zeben J; Allaart CF; Kloppenburg M
Lancet; 2019 Nov; 394(10213):1993-2001. PubMed ID: 31727410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
